Press Release Summary:
Featuring ColourSure™ technology, OneTouch Verio Flex™ shows arrow pointing to whether result is low (blue), within range (green), or high (red). Meter's ranges can be customized to each person's blood sugar target range, as recommended by their healthcare provider. Requiring just 0.4 Âµl of blood which can be applied to either side of test strip, meter includes BluetoothÂ® wirelessÂ technology for patients seeking connectivity with iOS and Android devices.
Original Press Release:
New OneTouch Verio Flex(TM) Blood Glucose Meter Takes the Guesswork Out of Blood Sugar Test Results
BURNABY, BC, - LifeScan Canada, a division of Johnson & Johnson Inc. is pleased to introduce the new OneTouch Verio Flex™ blood glucose meter, the latest addition to the OneTouch Verio® family of meters, designed to make self-monitoring of blood glucose (SMBG) simple to do anytime, anywhere, quickly and accurately.
For the nearly three million Canadians living with diabetes, (i) self-monitoring of blood glucose is an integral part of managing blood glucose and overall diabetes management. However, 50 per cent of patients do not achieve the recommended targets set by their healthcare professionals. (ii) Research suggests that when people living with diabetes know their blood glucose readings are in and out of range, it may help them stay in better control or reach their blood glucose goals.*
"Many people living with diabetes do not understand their blood glucose number or what to do about it. This can lead to serious consequences, particularly for those who have blood glucose levels that frequently fall out of the target range," says Lori Berard, Nurse Manager, WRHA Health Sciences Centre, Winnipeg Diabetes Research Group. "There are new technologies that have built in support systems, such as using colours, to teach people when they are in or out of range. There is potential that new blood glucose meters containing these features may assist with self-management decisions."
The OneTouch Verio Flex™ meter features ColourSure™ technology that instantly shows when your blood glucose results are in or out of range. The OneTouch Verio Flex™ meter's ranges can be customized to each person's blood sugar target range, as recommended by their healthcare provider. With each test, the meter display shows an arrow pointing to whether a result is low (blue), within range (green) or high (red), per the user's pre-set target range. With a compact, slim design, the OneTouch Verio Flex™ fits comfortably into a patient's hand and is easy to take on the go.
OneTouch Verio Flex™ System Key Features
-- Meets all the criteria of the most current ISO 15197:2013 standard as do all meters in the OneTouch Verio® family.
-- Is the third meter to use OneTouch Verio® test strips that require only a small amount of blood (0.4 ul) and offer easy application of blood to either side of the test strip.
-- While the OneTouch Verio Flex™ meter is ideal for most patients on its own, it also features BlueTooth® wireless technology for patients seeking connectivity with their iOS and Android devices.
People living with diabetes can find out more about the new OneTouch Verio Flex™ meter by talking to their healthcare professional and by visiting www.OneTouch.ca.
*Nine out of 10 healthcare professionals (HCPs) agreed in a Market Research study of 76 HCPs conducted in the USA, Aug. 2014.
About LifeScan Canada
LifeScan, the manufacturer of OneTouch® blood glucose monitoring products, is dedicated to creating a world without limits for people with diabetes. For information about diabetes care and OneTouch® products and services, visit www.OneTouch.ca.
*The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG. Inc., and any use of such marks by LifeScan Scotland Ltd. is under license. Other trademarks and trade names are those of their respective owners.
(i) Canadian Diabetes Association. Diabetes Facts. Available at: http://www.diabetes.ca/files/Diabetes_Fact_Sheet.pdf. Accessed on October 5, 2015.
(ii) Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32 (2):63-71.